NYSE:NVRO - Nevro Stock Price, Forecast & News

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro Corp (NYSE:NVRO) announced its quarterly earnings data on Wednesday, November, 6th. The medical equipment provider reported ($0.58) EPS for the quarter, beating the Zacks' consensus estimate of ($0.85) by $0.27. The medical equipment provider earned $100.16 million during the quarter, compared to analysts' expectations of $92.27 million. The company's revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.37) earnings per share. View Nevro's Earnings History.

Nevro is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Nevro.

Nevro will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Nevro updated its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $114.4-114.4 million, compared to the consensus revenue estimate of $109.73 million.

12 analysts have issued 1 year price targets for Nevro's stock. Their forecasts range from $65.00 to $150.00. On average, they anticipate Nevro's stock price to reach $103.83 in the next twelve months. This suggests that the stock has a possible downside of 25.7%. View Analyst Price Targets for Nevro.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.

News articles about NVRO stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nevro earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Nevro.

Nevro saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 2,610,000 shares, a decrease of 9.1% from the January 15th total of 2,870,000 shares. Based on an average daily volume of 443,000 shares, the days-to-cover ratio is currently 5.9 days. Approximately 8.8% of the shares of the stock are short sold. View Nevro's Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Incyte (INCY), Micron Technology (MU), Starbucks (SBUX), ABIOMED (ABMD), Celgene (CELG) and Intercept Pharmaceuticals (ICPT).

Nevro's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (6.17%), Franklin Resources Inc. (4.30%), Jackson Square Partners LLC (3.91%), Perceptive Advisors LLC (2.46%), State Street Corp (2.29%) and Lord Abbett & CO. LLC (1.92%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Shawn Mccormick and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Jackson Square Partners LLC, Perceptive Advisors LLC, Point72 Asset Management L.P., Franklin Resources Inc., Barclays PLC, Spark Investment Management LLC and Lord Abbett & CO. LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch and Shawn Mccormick. View Insider Buying and Selling for Nevro.

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Renaissance Technologies LLC, Partner Fund Management L.P., State of New Jersey Common Pension Fund D, Delta Investment Management LLC, Goldman Sachs Group Inc. and Fred Alger Management LLC. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $139.66.